Assembly Biosciences, Inc.
ASMB Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$19.84
KIRA · Stoqly’s AI analyst, in plain words
- Assembly Biosciences, Inc. had $72.3M of revenue in fiscal 2025, up 153.5% on the year before. Over five years, revenue changed −1.8% a year on average.
- Its operating margin was −16.8%, up 142.5 pts: of every 100 in sales, about −17 is left after running the business.
- Assembly Biosciences, Inc. lost $6.1M in fiscal 2025.
- Free cash flow was −$41.2M in fiscal 2025, −56.9% of revenue.
Market cap
$374M
P/E
16.4x
Revenue
$72.3M
Net income
−$6.1M
Free cash flow
−$41.2M
Operating margin
−16.8%
Assembly Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+153.5%
Yes. Sales grew 153.5% last year.
Does it make a profit?
−8.5%
No. It lost money last year.
Does profit turn into cash?
−56.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
16.4x
One share costs 16.4 times its yearly profit per share.
What Assembly Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- ASSEMBLY BIOSCIENCES, INC.
- CIK
- 0001426800
Assembly Biosciences, Inc. · ASMB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.3M | $0.0M | $7.2M | $28.5M | $72.3M |
| Revenue growth | −92.1% | −100.0% | — | 298.2% | 153.5% |
| Operating margin | −2,121.7% | — | −902.5% | −159.3% | −16.8% |
| Net income | −$130M | −$93.1M | −$61.2M | −$40.2M | −$6.1M |
| Net margin | −2,076.4% | — | −854.8% | −140.9% | −8.5% |
| Diluted EPS | −$3.00 | −$23.08 | −$13.38 | −$6.69 | −$0.55 |
| Cash | |||||
| Cash from operations | −$93.4M | −$84.5M | $22.7M | −$51.1M | −$41.1M |
| Capital expenditure | $3.1M | $0.1M | $0.3M | $0.0M | $0.1M |
| Free cash flow | −$96.5M | −$84.6M | $22.5M | −$51.1M | −$41.2M |
| FCF margin | −1,542.9% | — | 313.9% | −179.3% | −56.9% |
| Share count change | 22.2% | −90.7% | 13.5% | 31.2% | 86.7% |
| Debt and strength | |||||
| Cash and short-term investments | $147M | $91.6M | $130M | $112M | $248M |
| Shareholders' equity | $169M | $82.7M | $41.1M | $33.4M | $207M |
| Current ratio | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Returns and quality | |||||
| Return on equity | −63.4% | −74.0% | −98.9% | −107.9% | −5.1% |
| Return on tangible equity | −76.9% | −112.6% | −149.0% | −120.4% | −3.0% |
| Piotroski F-score | 2 | 2 | 4 | 2 | 3 |
| Altman Z'' | −2.7 | −19.7 | −16.9 | −21.0 | −1.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Assembly Biosciences, Inc. · ASMB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.84 a share, the company is worth $374M: 16.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001426800). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.